These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18758307)

  • 1. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
    Huang CH; Millenson MM; Sherman EJ; Borghaei H; Mintzer DM; Cohen RB; Staddon AP; Seldomridge J; Treat OJ; Tuttle H; Ruth KJ; Langer CJ
    J Thorac Oncol; 2008 Sep; 3(9):1032-8. PubMed ID: 18758307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
    Neubauer MA; Garfield DH; Kuerfler PR; Raju RN; Lindquist DL; Soo EW; Khan M; Boehm KA; Asmar L;
    Lung Cancer; 2005 Jan; 47(1):121-7. PubMed ID: 15603862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    J Thorac Oncol; 2006 Jul; 1(6):545-50. PubMed ID: 17409915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
    Spiridonidis CH; Laufman LR; Carman L; Moore T; Blair S; Jones J; George C; Patel T; Roach R; Rupert R; Zangmeister J; Colborn D; Kuebler JP
    Ann Oncol; 2001 Jan; 12(1):89-94. PubMed ID: 11249055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
    Chiappori A; Simon G; Williams C; Haura E; Rocha-Lima C; Wagner H; Bepler G; Antonia S
    Oncology; 2005; 68(4-6):382-90. PubMed ID: 16020967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.